Peptide Atlas · Peptide

Thymopentin (TP5)

In a double-blind trial in 100 patients with moderate to severe atopic dermatitis, six weeks of daily subcutaneous thymopentin reduced clinical severity, itching and redness more than placebo.

emerging

provisional
PubChem 451417
2 citations
0 discussions
0 followers
RKDVY
TP5
Timunox
thymopoietin (32-36)

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

emerging — human data exists, and it is thin or contested

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

- emerging
  Claim: Thymopentin reduced atopic dermatitis severity versus placebo (RCT, n=100) standing
- resolved
Thymopentin therapy reduces the clinical severity of atopic dermatitis.
Leung DY, Hirsch RL, Schneider L, Moody C, Takaoka R, Li SH, Meyerson LA, Mariam SG, Goldstein G, Hanifin JM
pmid 2185294
- emerging
  Claim: Thymopentin improved hepatitis B vaccine response in hemodialysis non-responders (RCT, n=40) standing
- resolved
Controlled trial of thymopentin in hemodialysis patients who fail to respond to hepatitis B vaccination.
Donati D, Gastaldi L
pmid 3065661

A claim's standing is its latest row in an append-only history; a tombstone names the later evidence and the reason. The Graveyard and the Resurrection Yard.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.